Abetalipoproteinemia

Lore & Background

Abetalipoproteinemia affects the absorption of dietary fats, cholesterol, and certain vitamins. People with this disorder are unable to make certain lipoproteins, leading to a multiple vitamin deficiency affecting vitamins A, D, E, and K, with many observed effects due to vitamin E deficiency in particular. Initial symptoms appear in infancy and include failure to thrive, steatorrhea (fatty, pale stools), frothy stools, foul-smelling stools, and a protruding abdomen. Later symptoms may include intellectual disability, ataxia, muscle weakness, slurred speech, lordosis, kyphoscoliosis, progressive decreased vision, and reflex and proprioception problems.

Reader's Guide

Abetalipoproteinemia is significant as a model for understanding lipoprotein metabolism and the consequences of fat-soluble vitamin deficiencies. The disorder highlights the critical role of microsomal triglyceride transfer protein in beta-lipoprotein formation and the transport of fats and vitamins. Diagnosis involves stool sampling, peripheral blood smear showing acanthocytes, low plasma chylomicron levels, and absence of apolipoprotein B, with genetic testing confirming the mutation. Treatment focuses on rigorous dieting with high-dose vitamin E therapy, which helps restore lipoproteins and slow neurological deterioration. Prognosis varies with severity of neurological dysfunction; early treatment can reverse neurologic sequelae and prevent further deterioration. The condition underscores the importance of early diagnosis and the potential for managing a rare genetic disease through dietary intervention and supplementation.

Did You Know?

• Abetalipoproteinemia is also known as Bassen–Kornzweig syndrome, microsomal triglyceride transfer protein deficiency disease, MTP deficiency, and betalipoprotein deficiency syndrome.
• The disorder is caused by mutations in the MTTP gene, which provides instructions for making microsomal triglyceride transfer protein.
• Approximately 80–99% of individuals exhibit malabsorption of fats and fat-soluble vitamins.
• High-dose vitamin E therapy primarily prevents or slows neurological and retinal damage but does not correct the underlying lipoprotein deficiency.

From Infancy to Adulthood: A Progressive Clinical Picture

Abetalipoproteinemia announces itself early. Within the first months of life—when pancreatic lipase has not yet become fully active—infants typically display a constellation of gastrointestinal and growth-related signs. Failure to thrive, fatty and pale stools, frothy or foul-smelling bowel movements, and a visibly protruding abdomen are among the earliest clues. Stools may even contain visible chunks of undigested fat or traces of blood. As children grow, the condition's reach expands well beyond the gut. Between thirty and seventy-nine percent of affected individuals develop neurological and ocular complications, including ataxia, reduced tendon reflexes, muscular hypotonia, and abnormalities of retinal pigmentation. Slurred speech, progressive loss of vision, and curvature of the spine in the form of lordosis and kyphoscoliosis tend to accumulate with age. By their thirties or forties, many adults face mounting difficulty with balance and gait. Roughly eighty to ninety-nine percent of patients show clear malabsorption of dietary fats and fat-soluble vitamins, making the gastrointestinal signature nearly universal.

A Single Gene, A Global Rarity

Abetalipoproteinemia traces its origin to mutations in the MTTP gene, which encodes the microsomal triglyceride transfer protein—a molecule indispensable for assembling beta-lipoproteins. In the vast majority of cases, the genetic defect produces a truncated, abnormally short version of this protein, effectively halting the body's ability to synthesize and export the lipoproteins needed to carry fats, cholesterol, and fat-soluble vitamins through the bloodstream. Because the disorder follows an autosomal recessive inheritance pattern, a child must inherit two faulty copies of the gene—one from each parent—to manifest the disease. Carriers with only one defective copy remain asymptomatic. The condition is extraordinarily uncommon: since physicians Bassen and Kornzweig first described it in 1950, roughly one hundred cases have been documented worldwide. It is important to distinguish abetalipoproteinemia from familial dysbetalipoproteinemia, a separate lipid disorder with a different genetic and clinical profile. The disease carries several alternative names in the medical literature, including Bassen–Kornzweig syndrome and microsomal triglyceride transfer protein deficiency disease.

Beyond the Gut: Multi-System Consequences

Although the primary defect lies in intestinal fat absorption, the downstream effects of abetalipoproteinemia ripple through virtually every major organ system. The inability to produce functional lipoproteins—molecular carriers that package cholesterol and triglycerides for transport—triggers a cascade of nutritional deficits. Fat-soluble vitamins A, D, E, and K all fall to critically low levels, yet vitamin E deficiency in particular drives much of the neurological damage. The spinocerebellar and dorsal column tracts of the central nervous system undergo progressive degeneration, manifesting as loss of reflexes, impaired proprioception, tremors, slurred speech, and peripheral neuropathy characterized by numbness, burning, or tingling in the extremities. The skeletal system is equally vulnerable, with lordosis, kyphoscoliosis, and pes cavus appearing over time. Vitamin A deficiency can erode retinal function to the point of near-blindness, while vitamin K insufficiency impairs clotting and leads to abnormal bleeding episodes. If left untreated, the cumulative toll includes blindness, cognitive decline, and irreversible loss of peripheral nerve function.

Identifying an Invisible Defect

Diagnosing abetalipoproteinemia requires piecing together several clinical and laboratory clues, no single one of which is definitive on its own. A typical initial workup includes stool sampling to detect steatorrhea, a peripheral blood smear, and a fasting lipid panel. The blood smear often reveals acanthocytes—spiny, abnormally shaped red blood cells—while plasma chylomicron levels remain strikingly low because the body cannot assemble or export them. The complete absence of apolipoprotein B in serum is a hallmark finding. Because the disease is so rare, confirmatory genetic testing of the MTTP gene is usually reserved for later in the diagnostic pathway rather than ordered upfront. Intestinal biopsy can show lipid-filled vacuoles within enterocytes, reflecting the cells' inability to package absorbed fats into chylomicrons; this same packaging failure allows lipids to accumulate at the cell surface and even in the liver, producing hepatic steatosis. For families with a known carrier status, prenatal genetic testing offers the possibility of identifying affected fetuses before birth.